---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-007211"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T02:49:44.259710+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Agenus reports Q3 net loss $56.7M, cash $218.2M; botensilimab Phase 2 trials initiated

## Summary
- Q3 2022 net loss $56.7M ($0.19/sh) vs prior-year net income; revenue $22.8M, down from $253M largely due to prior milestone.
- Cash and investments $218.2M vs $306.9M at Dec 2021; cash used in operations $32.2M in Q3.
- Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS colorectal cancer and melanoma.
- Expanded leadership: Patricia Carlos named Chief Regulatory, Quality & Safety Officer; Todd Yancey as Senior Clinical Advisor.
- Partner programs advancing: BMS, Merck, Incyte ongoing Phase 2/1 trials for discovered assets.

## SEC filing metadata
- accession: 0001171843-22-007211
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000117184322007211/0001171843-22-007211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000117184322007211/f8k_110722.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-007211
- JSON: https://secwatch.observer/filing/0001171843-22-007211.json
- Plain text: https://secwatch.observer/filing/0001171843-22-007211.txt

## Key facts
- Earnings Releases
  AGENUS INC reported the third quarter of 2022 results: revenue $22.8 million, net income $56.7 million, EPS $0.19 per share.
  - Period: the third quarter of 2022
  - Revenue: $22.8 million
  - Net income: $56.7 million
  - EPS: $0.19 per share
  - Result: reported results
  source text: We recognized revenue of $22.8 million and incurred a net loss of $56.7 million, or $0.19 per share, for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1098972/000117184322007211/0001171843-22-007211-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.